Abstract
1. Stop injection/infusion immediately
2. Get extravasation kit
3. Put on (sterile) gloves
4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Original articles
Legha SS, Gutterman JU, Hall SW, et al: Phase I clinical investigation of 4´-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 249992), a new acridine derivative. Cancer Res 38: 3712–3716, 1978.
Soble MJ, Dorr RT, Plezia P, et al: Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics. Cancer Chemother Pharmacol 20: 33–36, 1987.
Secondary literature
Dorr RT: Extravasation of vesicant antineoplastics: clinical and experimental findings. Ariz Med 38: 271–275, 1981.
Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.
Schneider G: Paravasate von Zytostatika. Diagnostik und -Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.
Dorr RT: Pharmacologic management of vesicant -chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer -Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.
Louie AC, Issell BF: Amsacrine (AMSA) – a clinical review. J Clin Oncol 3: 562–592, 1985.
Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.
Krämer I, Stützle M: Zytostatika-Paravasation – Wie ist -vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.
Bertelli G: Prevention and management of extravasation of -cytotoxic drugs. Drug Safety 12: 245–255, 1995.
Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA–Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Mon-ographien. Verlag Heiner Biller, vol 1, 2nd edition: A42–44, 1997.
Dorr RT, Von Hoff DD: Drug monographs: amsacrine. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. -Appleton & Lange, 2nd edition: 182–189, 1994.
Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.
Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.
Summary of product characteristics Amsidyl® (Switzerland), Pfizer, April 2003.
Allwood M: Chemotherapeutic agents: amsacrine. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 268–270, 2002.
Gain M, Melzer S, Meyer-Jürshof A, et al: Amsacrin: Behandlung von Paravasaten. In: Gain M, et al (eds) -ADKA-Zytostatika-Handbuch, -Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 5: 20, 2001.
Jordan K, Grothe W, Schmoll HJ: Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). Amsacrine. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_12
Download citation
DOI: https://doi.org/10.1007/978-3-211-88893-3_12
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-88889-6
Online ISBN: 978-3-211-88893-3
eBook Packages: MedicineMedicine (R0)